India's Indigenous HPV Test Meets International Standards: A Major Breakthrough in Cervical Cancer Screening

New Delhi, June 12, 2026. India has achieved an important milestone in the prevention of cervical cancer. The country's first indigenous HPV (human papillomavirus) DNA test has been successfully validated, meeting international standards for cervical cancer screening. This success is the result of collaboration between AIIMS New Delhi, various ICMR institutions and the cancer research agency of the World Health Organization. The study has been published in the 'International Journal of Cancer'.

Which Test Was Validated

In this study, Molbio Diagnostics' 'Truenat HPV-HR Plus' test met the validation criteria established by the International Agency for Research on Cancer (IARC), the WHO's specialised cancer research agency. In all, four point-of-care tests were evaluated, of which two were found suitable for use in the National Programme. This is a major step forward for India's cervical cancer elimination efforts and its broader goal of universal, affordable screening.

What Makes This Test Special

The biggest strength of this indigenous test is its accuracy and affordability. The test targets 8 high-risk HPV types. Because of this narrow but focused approach, it avoids detecting the transient, low-risk infections that 14-type tests often pick up. It maintained an exceptional relative clinical specificity of 0.99, which is expected to drastically reduce unnecessary secondary referrals, costly over-triage and patient anxiety, while keeping the test simple and quick to administer at the point of care.

The Collaborating Institutions

The study was conducted in collaboration with several leading Indian and international institutions. These include AIIMS New Delhi, the ICMR-National Institute of Cancer Prevention and Research, the ICMR-National Institute for Research in Reproductive and Child Health, the France-based International Agency for Research on Cancer, and the Biotechnology Industry Research Assistance Council under the Department of Biotechnology, Government of India. This broad collaboration underscores the credibility of the study and shows that Indian research institutions are working in line with global standards.

Why It Matters

Cervical cancer remains one of the leading causes of cancer-related deaths among Indian women. The biggest reason for this is the lack of timely screening and diagnosis. Until now, access to cervical cancer screening in the country has been limited, especially in rural and low-resource areas. The development of an affordable and reliable indigenous test could help bridge this gap. The test specifically targets women above 30 years of age, who fall into the group most at risk from the disease.

A Model for Low-Resource Countries

Experts believe that India's validated HPV test could become a model for cervical cancer screening not only for the country but also for other low-resource nations around the world. Point-of-care technology means that the test can be performed even at local health centres, without the need for large laboratories. This could extend the reach of screening to areas where health facilities are limited. It is also a significant success for the 'Make in India' initiative in the field of medical diagnostics.

Combining Vaccination and Screening

Cervical cancer is one of the few cancers that can be almost eliminated through prevention and timely screening. On one hand, an HPV vaccination programme can protect young girls from infection, while on the other hand this indigenous test will help detect the disease early in adult women. Combining both strategies could help India move rapidly towards its goal of cervical cancer elimination. The World Health Organization has also declared the elimination of cervical cancer a global priority.

A Step Towards Health Self-Reliance

Beyond its clinical value, the validation of an indigenous HPV test carries strategic significance for India's health sector. For years, the country relied heavily on imported diagnostic kits, which were often expensive and difficult to scale across a population of more than a billion. A locally developed, internationally validated test reduces this dependence and strengthens domestic manufacturing capacity. It also positions Indian diagnostics firms to export affordable solutions to other developing nations facing similar cervical cancer burdens, turning a public health achievement into a potential model for South-South cooperation in medical technology.

What's Next

The indigenous HPV test is now expected to be widely incorporated into the National Cervical Cancer Screening Programme. This success is another strong step for India in the health sector in the direction of a self-reliant India. If the test is implemented correctly on a nationwide scale, it could play a decisive role in saving the lives of thousands of women and reducing the burden of cervical cancer in the years to come. Alongside this, promoting public awareness and screening uptake will be equally important.